These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Jenkins SG, Brown SD, Farrell DJ. Ann Clin Microbiol Antimicrob; 2008 Jan 11; 7():1. PubMed ID: 18190701 [Abstract] [Full Text] [Related]
3. Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002. Farrell DJ, Jenkins SG. J Antimicrob Chemother; 2004 Aug 11; 54 Suppl 1():i17-22. PubMed ID: 15265832 [Abstract] [Full Text] [Related]
5. Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3. Jenkins SG, Farrell DJ, Patel M, Lavin BS. J Infect; 2005 Dec 11; 51(5):355-63. PubMed ID: 15950288 [Abstract] [Full Text] [Related]
7. Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study. Brown SD, Farrell DJ, Morrissey I. J Clin Microbiol; 2004 Nov 11; 42(11):4980-7. PubMed ID: 15528684 [Abstract] [Full Text] [Related]
8. Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children. Sunakawa K, Farrell DJ. Ann Clin Microbiol Antimicrob; 2007 Aug 13; 6():7. PubMed ID: 17697316 [Abstract] [Full Text] [Related]
9. Comparative activity of telithromycin against macrolide-resistant isolates of Streptococcus pneumoniae: results of two years of the PROTEKT surveillance study. Schito GC, Marchese A, Elkharrat D, Farrell DJ, PROTEKT Study Group. J Chemother; 2004 Feb 13; 16(1):13-22. PubMed ID: 15077994 [Abstract] [Full Text] [Related]
10. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the Ketolide Telithromycin: results from the PROTEKT surveillance study (1999-2000). Reinert RR, Rodloff AC, Halle E, Baer W, Beyreiss B, Seifert H, Wichelhaus TA, Maass M, Mehl M. Chemotherapy; 2004 Jun 13; 50(3):143-51. PubMed ID: 15272227 [Abstract] [Full Text] [Related]
11. Antibacterial resistance patterns in Streptococcus pneumoniae isolated from elderly patients: PROTEKT years 1-5 (1999-2004). Cantón R, Unal S, Farrell DJ. Int J Antimicrob Agents; 2007 Dec 13; 30(6):546-50. PubMed ID: 17931834 [Abstract] [Full Text] [Related]
12. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001. Stratton CW, Brown SD. Clin Ther; 2004 Apr 13; 26(4):522-30. PubMed ID: 15189749 [Abstract] [Full Text] [Related]